Allogeneic Hematopoietic Cell Transplantation is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: a Systematic Review/Meta-analysis

ConclusionThis systematic review represents the best available evidence supporting allo-HCT in BPDCN, especially when offered in CR1. Use of myeloablative (MAC) allo-HCT results in lower pooled relapse rates (18% vs. 40%). A prospective comparative study will be, ideally, needed to determine the impact of intensity of the conditioning regimen on post-allograft relapse.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research